Sanofi exhibit strong financial dynamics in recent quarters, with impressive performance in Q3 2024. Burnishing Q3 results was a whopping 381% growth in
Beyfortus sales, ahead of what was predicted by market analysts. Early vaccine sales have also boosted profits, alongside growth in
Dupixent and other vaccine sales. This solid performance enabled Sanofi to raise its 2024 forecast. The company also backed fibrosis biotech
Agomab in its $89M Series D. More strategic advancements emerged from exclusive negotiations for a sale of a 50% stake in its €16B consumer health unit,
Opella, to CD&R. A deal seems to be in place, despite varying responses, including protests over the sale from employees and concerns over job guarantees from the French government. Recent steps into the radiopharma field with Orano, in a $326M deal, and strong R&D partnerships with AQEMIA, further reinforced Sanofi's strategic portfolio of advanced therapies. Despite potential material drawbacks, like the withdrawal of Trodelvy’s Bladder Cancer, Sanofi appeared determined to maintain momentum in a diverse range of healthcare and business sectors.
Sanofi News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 26 Oct 2024 12:14:10 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor 5
